Cellectar Biosciences, Inc. — 2013 Second-Quarter Filing Summary
Filing identity: The supplied 10-Q is filed by Novelos Therapeutics, Inc., a development-stage company, for the quarter ended June 30, 2013. It describes Cellectar’s cancer-drug development programs following the companies’ 2011 business combination; it is not filed under the name Cellectar Biosciences. Financial comparisons are with the three and six months ended June 30, 2012.
Business context and operating results
The company develops oncology imaging and therapeutic candidates: LIGHT (I-124-CLR1404), in Phase 1–2 trials across 11 solid-tumor indications; HOT (I-131-CLR1404), in a Phase 1b dose-escalation trial; and preclinical optical imaging candidate GLOW2. The company reported no product revenue. Profit margins are not applicable; the business continues to incur development-stage losses.
| Metric | Q2 2013 | Q2 2012 | Six months 2013 | Six months 2012 |
|---|---|---|---|---|
| Research and development expense | $1.649 million | $1.315 million | $3.239 million | $2.643 million |
| General and administrative expense | $1.074 million | $0.897 million | $2.195 million | $1.895 million |
| Operating loss | $2.723 million | $2.212 million | $5.435 million | $4.537 million |
| Net loss | $2.064 million | $2.231 million | $5.518 million | $4.588 million |
| Basic and diluted loss per share | $0.04 | $0.06 | $0.10 | $0.12 |
The Q2 net loss improved despite a higher operating loss, largely reflecting a $660,000 noncash gain from revaluing derivative warrants, versus a $17,000 loss in Q2 2012. For the first half, results included a $745,000 noncash loss on issuing derivative warrants and a $666,000 noncash revaluation gain. R&D increases reflected clinical-trial materials and manufacturing work, GLOW2 preclinical activity, and additional personnel; G&A rose mainly with consulting, insurance, legal, and payroll costs.
Cash, liquidity, and capital structure
- At June 30, 2013, cash and cash equivalents were $5.828 million, up from $4.678 million at year-end 2012. An additional $1.878 million was restricted and contractually designated for the proposed LIGHT manufacturing facility; it is not included in available operating cash. Another $55,000 was restricted under a lease.
- Operating activities used $3.923 million in the first half of 2013, compared with $3.200 million in the first half of 2012. Financing provided $5.045 million, primarily from the February public offering; investing activities provided $29,000.
- The February 2013 offering generated $5.5 million gross and $4.975 million net proceeds, issuing 11 million shares and warrants. Common shares outstanding increased from 46.398 million at December 31, 2012 to 57.398 million at June 30, 2013; 57.398 million were reported outstanding on August 9.
- Total liabilities were $6.681 million, including a $5.067 million current derivative-warrant liability, $450,000 in long-term notes payable, and capital-lease obligations. The warrant liability rose from $13,000 at year-end, primarily following the February financing and fair-value changes. Stockholders’ equity was $5.444 million; the filing reports negative working capital of $60,254.
Outlook, risks, and notable developments
- Management said available operating cash was expected to fund operations through the end of 2013. Funding beyond then depends on raising capital, a strategic transaction, or another source; no financing negotiations were reported, and there is no assurance funding will be available. The company expects continuing operating losses.
- The company was no longer pursuing construction of its estimated $3 million in-house LIGHT facility and was transferring the manufacturing process to a contract manufacturer to support larger-scale production. The $1.878 million restricted balance remained designated for the facility.
- Management expected to submit a GLOW2 IND in Q4 2013 and begin clinical trials shortly thereafter. This is a stated plan, not a guarantee. LIGHT and HOT trial progress and manufacturing arrangements remain important development and execution risks.
- After quarter-end, CEO and President Harry Palmin announced he would step down once a successor was named; the search was underway. Clinical Development VP Kimberly Hawkins resigned effective August 9, and Kevin Kozak was engaged as consulting Chief Medical Officer. Related amended employment and retention arrangements could result in payments, including up to $392,000 under two executive retention agreements.
- A dispute with ZAO BAM over rights to legacy NOV-002 compounds remained on appeal after a trial-court ruling in Novelos’s favor. The company said it did not expect a material adverse effect. The filing also identifies risks from key-personnel departures, clinical and regulatory failure, and dependence on additional financing.
Most important facts for investors to verify
- Whether new financing or a strategic transaction was secured after the filing, and whether cash runway extended beyond management’s end-of-2013 estimate.
- How much of reported cash is available for operations versus contractually restricted for manufacturing, and the current status and cost of contract manufacturing LIGHT.
- Subsequent clinical and regulatory milestones for LIGHT, HOT, and GLOW2, including whether the planned GLOW2 IND and trial timing were achieved.
- The dilution and potential accounting volatility from 36.8 million outstanding warrants, including down-round provisions, as well as outstanding options.
- Leadership succession, related compensation obligations, and the status and potential outcome of the ZAO BAM appeal.